{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-028331","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.276701+00:00","generated_at":"2026-06-23T03:53:26.066816+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Anebulo Pharmaceuticals adopts amended bylaws to comply with universal proxy rules","bullets":["Board of Directors adopted Amended and Restated Bylaws on October 11, 2022.","Updated advance notice procedures for stockholder proposals to require additional information.","Added classified Board provision consistent with existing certificate of incorporation.","Implemented supermajority stockholder vote requirement for any future bylaw amendments.","Removed President's authority to call special meetings of stockholders or the Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-028331","json":"https://secwatch.observer/filing/0001493152-22-028331.json","markdown":"https://secwatch.observer/filing/0001493152-22-028331.md","text":"https://secwatch.observer/filing/0001493152-22-028331.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222028331/0001493152-22-028331-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222028331/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:53:26.066816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}